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ABSTRACT
Introduction: To compare biologic disease-
modifying antirheumatic drug therapy
persistence between biologics among patients
with rheumatoid arthritis (RA) who previously
used C1 other biologic.
Methods: Using a large United States
administrative claims dataset, we identified
adult patients with RA initiating abatacept,
adalimumab, certolizumab, etanercept,
golimumab, infliximab, or tocilizumab
between January 1, 2010 and January 1, 2012
(initiation date = index). Patients were required
to have used C1 other biologic before index.
Outcomes were biologic persistence, defined in
two alternative ways: (1) time from initiation
until switching to a different biologic (time to
switch) and (2) time from initiation until
switching or the first occurrence of a 90-day
gap in treatment with the initiated biologic
(time to switch/discontinuation). Rituximab
was excluded from analyses due to retreatment
based on clinical evaluation, which complicates
the measurement of persistence. Multivariable
survival analyses compared persistence
outcomes between tocilizumab and the other
biologics, adjusting for patient characteristics.
Results: The sample comprised 9,782 biologic
initiations; mean age 54 years and 82% female.
Compared with tocilizumab, the hazards of
switching biologic therapy were significantly
higher for abatacept [hazard ratio (HR) = 1.19,
P = 0.041], adalimumab (HR = 1.39, P\0.001),
certolizumab (HR = 1.39,P\0.001), golimumab
(HR = 1.20, P = 0.047), and infliximab
(HR = 1.33, P\0.001), but not significantly
different for etanercept (HR = 1.19, P = 0.095);
the hazards of switching/discontinuing biologic
therapy were significantly higher for
adalimumab (HR = 1.16, P = 0.014) and
certolizumab (HR = 1.15, P\0.012), but not
significantly different for abatacept (HR = 1.08,
P = 0.229), etanercept (HR = 0.97, P = 0.644),
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golimumab (HR = 0.99, P = 0.829), and
infliximab (HR = 0.97, P = 0.721).
Conclusions: This is one of the first studies of
biologic persistence to focus specifically on
patients with RA who are not naı¨ve to biologic
treatment. Among patients with RA who
previously used C1 other biologic,
tocilizumab-treated patients had similar or
significantly better biologic persistence
compared with other biologics.
Keywords: Biologics; Persistence; Rheumatoid
arthritis; Switching
INTRODUCTION
The 2010 European League Against Rheumatism
(EULAR) and 2012 American College of
Rheumatology (ACR) recommendations on
rheumatoid arthritis (RA) management suggest
switching to a different disease-modifying
antirheumatic drug (DMARD) when biologic-
treated patients experience treatment failure,
lack of efficacy, or toxicity [1, 2]. Accordingly, a
switch between biologics may signal that the
therapy from which a patient has switched was
ultimately suboptimal for that patient; indeed,
lack of efficacy and adverse events are among the
most commonly documented reasons for
switching biologic therapies [3–5].
Very little information has been published
regarding biologic therapy persistence across
biologic agents in the real-world setting and
comparative information on biologic
persistence for certolizumab, golimumab, and
tocilizumab is unavailable. Furthermore, there
is little information on biologic persistence
among patients with RA who are not naı¨ve to
biologic treatment. Thus, the objective of this
retrospective, observational cohort study was to
compare biologic therapy persistence between
biologics among patients with RA who have
previously used at least one other biologic.
METHODS
Overview of Study Design
This was a retrospective, observational cohort
study based on administrative claims data. The
sample comprised patients with RA initiating
biologic therapy after previously using at least
one other biologic agent. Study outcomes were
biologic persistence, defined in two alternative
ways: (1) time from initiation until switching to
a different biologic (time to switch) and (2) time
from initiation until switching or the first
occurrence of a 90-day gap in treatment with
the initiated biologic (time to switch/
discontinuation).
Data and Setting
This study’s data were administrative claims
data extracted from the Truven Health
MarketScan (Truven Health, Ann Arbor, MI,
USA) Commercial Claims and Encounters
(Commercial) and Medicare Supplemental and
Coordination of Benefits (Medicare
Supplemental) databases. These databases
represent a non-probability sample and
comprise enrollment information and
inpatient medical, outpatient medical, and
outpatient pharmacy claims data for
individuals with employer-sponsored primary
or Medicare supplemental health insurance. No
patients in these databases are covered under
Medicaid insurance. In 2011 alone, the study
databases contained data for over 40 million
unique individuals. These databases have been
used in multiple published epidemiologic
evaluations related to RA [6].
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The study databases satisfy the conditions set
forth in Sections 164.514 (a)–(b)1ii of the
Health Insurance Portability and
Accountability Act of 1996 privacy rule
regarding the determination and
documentation of statistically de-identified
data. Because this study used only de-
identified patient records and does not involve
the collection, use, or transmittal of
individually identifiable data, Institutional
Review Board approval to conduct this study
was not necessary.
As described in greater detail below, study
variables were measured from the database
using enrollment records, International
Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes,
Current Procedural Technology 4th edition
(CPT-4) codes, Healthcare Common
Procedure Coding System (HCPCS) codes, and
National Drug Codes (NDCs), as appropriate [7].
Patient Selection Criteria
Patients included for study were patients with
RA initiating a biologic treatment after
previously using C1 other biologic. As
described below, patients were classified as
having RA on the basis of ICD-9-CM codes
recorded on their medical claims and exposure
to biologic therapy was identified on the basis of
a prescription fill or visit to a physician during
which an infusion was administered.
Specifically, patients were included in the
analysis if they met all of the following
selection criteria: initiated a biologic agent
(abatacept, adalimumab, certolizumab,
etanercept, golimumab, infliximab, or
tocilizumab) between January 1, 2010 and
January 1, 2012 (the dates of initiation for
biologic agents used during this period were
designated as the index dates); used at least one
other biologic at any time prior to the index
date (i.e., were not biologic naı¨ve); had at least
one non-diagnostic medical claim (i.e.,
excluding medical claims such as radiology
and venipuncture, which may represent
services that are used to diagnose or rule out
the presence of a condition) with a diagnosis of
RA (ICD-9-CM code 714.0x) between January 1,
2009 and March 31, 2012; were aged 18 years or
older on the index date; were continuously
enrolled for at least 6 months pre-index
(designated as the baseline period) and
3 months post-index; and had no medical
claims with diagnosis codes for any non-RA
indication of biologic agents (ankylosing
spondylitis, chronic lymphocytic leukemia,
Crohn’s disease, juvenile idiopathic arthritis,
polyarteritis nodosa, non-Hodgkin’s
lymphoma, plaque psoriasis, psoriatic arthritis,
ulcerative colitis, or Wegener’s granulomatosis)
within the baseline period. As described in
greater detail below, rituximab was excluded
from analyses due to retreatment based on
clinical evaluation, which complicates the
measurement of persistence.
An episode-based study design was used
wherein patients were allowed to contribute
multiple observations to the dataset, one for
each biologic they initiated sequentially during
the study period. Thus, patients were followed
forward in time after their first qualifying
biologic initiation to capture all subsequent
episodes of biologic use. Episodes of biologic use
began with initiation of a new biologic and
ended with switch to a different biologic, the
end of the study period (March 31, 2012), or
insurance disenrollment.
Biologic Therapy Persistence Outcomes
The study outcomes were biologic therapy
persistence, defined in two alternative ways:
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(1) time from initiation until switching to a
different biologic (time to switch) and (2) time
from initiation until switching or the first
occurrence of a 90-day gap in treatment with
the initiated biologic. The follow-up of patients,
who did not experience a switch, was censored
at the end of the study period (March 31, 2012)
or insurance disenrollment. As noted above,
rituximab was excluded from the analyses. This
is because courses of rituximab may be given
every 24 weeks or based on clinical evaluation,
we could not define a single time point from
which a 90-day gap in therapy exposure would
begin. Furthermore, because the re-treatment
interval for rituximab is no sooner than
4 months after the prior infusion, it is possible
that physicians would wait longer to switch
patients from RTX, as compared with other
biologics that have shorter re-treatment
intervals. Thus, we conservatively chose to
exclude rituximab from the analyses due to
the uniqueness of re-treatment, which can
complicate the measurement of persistence.
Rituximab use was still tracked, however, for
the purpose of identifying cases in which
patients switched to rituximab.
Covariates
The study covariates included patient
demographics and clinical characteristics
thought to potentially confound the
relationship between the persistence outcomes
and biologic agent. Patient demographics were
measured at index and are listed in Table 1.
Patient clinical characteristics were measured
throughout the baseline period and are listed in
Table 2 [8, 9]. Included in the list of clinical
characteristics was an administrative claims-
based index for RA severity (CIRAS) score,
which has been shown to have moderate
correlations with a previously validated records-
based index of severity that has established
construct validity and convergent validity with
the Disease Activity Score (DAS28) [10]. The
CIRAS assigns a numerical value based on
orders for inflammatory markers, number of
platelet counts and chemistry panels ordered,
rheumatoid factor, rehabilitation visits, age and
gender, presence of Felty’s syndrome and
number of rheumatology visits. Details on the
algorithm can be found in Ting et al. [10]. These
covariates are consistent with prior research
showing that demographic factors as well as
measures of comorbidity, medication and other
healthcare resource use to predict time to
biologic discontinuation [11].
Statistical Analysis
Bivariate analyses were used to display summary
statistics for the variable distributions, stratified
by biologic agent. The Kaplan–Meier (or product-
limit) method was used to estimate the
unadjusted probabilities of the persistence
outcomes at 1 and 2 years after initiation [12].
Multivariable Cox proportional hazards models
with the Huber-White ‘‘sandwich’’ variance
estimator—which accounted for the possibility
of multiple observations per patient—were used
to compare the persistence outcomesbetween the
biologic agents, adjusting for patient
demographics and clinical characteristics listed
in Tables 1 and 2 [13–15]. The variance inflation
factor was used to assess multi-collinearity of the
model’s independent variables [16]. Plots of
Schoenfeld residuals were used to assess whether
the model’s independent variables met the
proportionality assumption of the Cox
proportional hazards modeling approach [17]. In
the multivariable analyses, tocilizumab was
chosen as the reference category because for the
time period during which this study was
conducted, tocilizumab was the last entrant to
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the market and, among the more recently
approved biologics including certolizumab and
golimumab, had a unique (non-anti-TNF)
mechanism of action. The choice of tocilizumab
as the reference category therefore provided
comparative information between it and each of
Table 1 Patient demographics measured at index
Demographic TCZ ABA INF ADA CZP ETA GOL
N5 1,090 N5 1,759 N5 922 N5 2,179 N5 962 N5 1,675 N5 1,195














Female, % 83.1% 83.2% 81.2% 81.0% 80.1% 80.7% 82.3%
Geographic region, %
Northeast 12.3% 11.8% 13.3% 14.2% 13.8% 13.3% 11.1%
North Central 27.3% 28.1% 22.2% 25.0% 22.0% 26.3% 27.6%
South 39.0% 42.0% 43.5% 37.2% 44.5% 40.6% 40.1%
West 20.6% 17.1% 20.0% 22.9% 19.1% 19.0% 20.7%
Unknown 0.7% 1.0% 1.0% 0.7% 0.5% 0.8% 0.5%
Insurance plan type, %
Comprehensive 11.0% 13.8% 12.4% 10.1% 8.5% 10.0% 10.1%
EPO 1.7% 1.9% 1.3% 1.7% 2.4% 1.7% 1.7%
HMO 15.2% 14.1% 16.7% 16.4% 12.8% 14.1% 12.6%
Point of service 7.9% 8.2% 6.9% 7.7% 7.7% 8.1% 10.4%
PPO 53.9% 53.2% 55.0% 55.6% 58.2% 55.9% 57.6%
POS with
capitation
0.9% 0.9% 0.8% 0.6% 1.2% 0.5% 0.8%
CDHP 3.7% 2.9% 2.4% 3.7% 4.3% 4.8% 3.8%
HDHP 1.7% 1.8% 1.6% 1.9% 0.9% 1.7% 0.8%
Unknown 4.0% 3.2% 2.9% 2.5% 4.0% 3.0% 2.3%
Population density, %
Urban 84.9% 85.2% 83.8% 83.8% 85.9% 81.5% 82.8%
Rural 14.4% 13.8% 15.2% 15.6% 13.6% 17.8% 16.8%
Unknown 0.7% 1.0% 1.0% 0.7% 0.5% 0.7% 0.3%
Year of index, %
2010 33.4% 48.9% 47.7% 45.4% 46.3% 43.2% 60.2%
2011 66.6% 51.1% 52.3% 54.6% 53.7% 56.8% 39.8%
ABA abatacept, ADA adalimumab, CDHP Consumer Directed Health Plan, CZP certolizumab, EPO exclusive provider
organization, ETA etanercept, GOL golimumab, HDHP High Deductible Health Plan, HMO Health Maintenance
Organization, INF inﬂiximab, POS point of service, PPO preferred provider organization, SD standard deviation, TCZ
tocilizumab
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the other available biologics. All analyses were
performed using SAS version 9.2 (Cary, NC, USA).




From among 360,508 patients with at least one
non-diagnostic medical claim (i.e., excluding
medical claims such as radiology and
venipuncture, which may represent services that
are used to diagnose or rule out the presence of a
condition) for RA between January 1, 2009 and
March 31, 2012, a total of 16,999 initiations of
biologic therapy after use of at least one prior
biologic were identified. From among these
16,999 initiations, 138 were excluded because
they did not meet the study’s age criteria, an
additional 3,063 were excluded because they did
not meet the study’s continuous enrollment
criteria, an additional 3,106 were excluded
because they had at least one medical claim with
a diagnosis code for a non-RA indication of
biologic therapy, and 910 were excluded because
they were rituximab initiations. The final sample
comprised 9,782 biologic initiations.
Table 2 Patient clinical characteristics measured during 6-month (pre-index) baseline period
Clinical characteristic TCZ ABA INF ADA CZP ETA GOL
N5 1,090 N5 1,759 N5 922 N5 2,179 N5 962 N5 1,675 N5 1,195




3.7 (±1.2) 3.6 (±0.9)
NSAIDs, % 38.5% 39.3% 41.9% 41.8% 45.2% 42.8% 41.7%
Corticosteroids, % 80.8% 78.6% 76.7% 71.1% 74.3% 72.4% 69.5%
Analgesics, % 63.9% 58.6% 56.9% 52.6% 56.3% 58.0% 53.7%
Non-biologic DMARDs, mean
(±SD)




0.9 (±0.7) 0.9 (±0.7)
Extraarticular diseasea, % 5.5% 4.5% 3.4% 4.2% 4.2% 3.2% 4.1%




1.3 (±0.8) 1.3 (±0.9)

































drug = anti-TNF, %
49.5% 85.8% 72.5% 91.2% 85.1% 88.2% 87.3%
ABA abatacept, ADA adalimumab, CIRAS claims-based index for rheumatoid arthritis severity, CZP certolizumab, DCI
Deyo-Charlson comorbidity index, DMARD disease-modifying antirheumatic drug, ETA etanercept, GOL golimumab,
ICD-9-CM International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation, INF inﬂiximab, NDC National
Drug Code, NSAIDs non-steroidal anti-inﬂammatory drugs, SD standard deviation, TCZ tocilizumab, TNF tumor necrosis
factor-a
a Rheumatoid nodules, Sjo¨gren’s syndrome, retinal vasculitis, other vasculitis, Felty’s syndrome, or rheumatoid lung
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Tables 1 and 2 display patients’
demographics and baseline clinical
characteristics, respectively, stratified by
biologic agent. The average patient age ranged
from 52.5 years in golimumab-treated patients
to 55.4 in abatacept-treated patients. The
proportion of females ranged from 80.1% in
certolizumab-treated patients to 83.2% in
abatacept-treated patients. Across all biologics,
the average number of non-biologic DMARDs
used prior to initiation was approximately one.
Use of corticosteroids prior to initiation was
common, with proportions ranging from 69.5%
in golimumab-treated patients to 80.8% in
tocilizumab-treated patients.
Biologic Therapy Persistence
Table 3 displays probabilities of biologic
therapy persistence, as defined by time to
switch, at 1 and 2 years after initiation,
unadjusted for demographic or clinical
characteristics. A total of 2,553 switches to a
different biologic were observed. At 1 year
after initiation, the probability of persisting
on therapy without switching ranged from
68.8% in certolizumab-treated patients to
76.6% in tocilizumab-treated patients; at
2 years after initiation, these probabilities
ranged from 52.4% in certolizumab-treated
patients to 66.9% in etanercept-treated
patients.
Figure 1 displays the multivariable-adjusted
hazard ratios (HRs) for time to switch, treating
tocilizumab as reference category. Compared
with tocilizumab, the hazards of switching
biologic therapy were significantly higher for
abatacept (HR = 1.19, P = 0.041), adalimumab
(HR = 1.39, P\0.001), certolizumab
(HR = 1.39, P\0.001), golimumab (HR = 1.20,
P = 0.047), and infliximab (HR = 1.33,
P\0.001), but not significantly different for
etanercept (HR = 1.16, P = 0.095).
Table 4 displays probabilities of biologic
therapy persistence, as defined by time to
switch/discontinuation, at 1 and 2 years after
Table 3 Unadjusted probabilities of biologic DMARD therapy persistence (time to switch to different biologic DMARD)
at 1 and 2 years after initiation
Follow-up and persistence TCZ ABA INF ADA CZP ETA GOL
N5 1,090 N5 1,759 N5 922 N5 2,179 N5 962 N5 1,675 N5 1,195
Median days of follow-up
overalla
317 361 358 346 344 338 431
Median days of follow-up until
eventb
252 281 267 263 261 265 299
N switching to different biologic
DMARD
238 449 257 580 291 384 354
Unadjusted probability of biologic DMARD therapy persistence, %c
1 year after initiation 76.6 73.5 72.5 70.9 68.8 75.7 70.9
2 years after initiation 60.6 58.8 55.8 60.6 52.4 66.9 58.5
ABA abatacept, ADA adalimumab, CZP certolizumab, DMARD disease-modifying antirheumatic drug, ETA etanercept,
GOL golimumab, INF inﬂiximab, TCZ tocilizumab
a Days from initiation until disenrollment or March 31, 2012
b Days from initiation to switch to a different biologic DMARD or censoring at disenrollment or March 31, 2012
c Kaplan–Meier estimate
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Fig. 1 Multivariable-adjusted hazard ratios (HRs) for time
to non-persistence with biologic therapy (time to switch to
different biologic DMARD), treating TCZ as reference
category. See Appendix in the Electronic Supplementary
Material for full multivariable analysis results. *P\0.05 vs.
TCZ, **P\0.01 vs. TCZ. ABA abatacept, ADA
adalimumab, CI conﬁdence interval, CZP certolizumab,
DMARD disease-modifying antirheumatic drug, ETA
etanercept, GOL golimumab, INF inﬂiximab, TCZ
tocilizumab
Table 4 Unadjusted probabilities of biologic DMARD therapy persistence (time to time to switch to different biologic
DMARD/discontinuation of the initiated biologic DMARD) at 1 and 2 years after initiation
Follow-up and persistence TCZ ABA INF ADA CZP ETA GOL
N5 1,090 N5 1,759 N5 922 N5 2,179 N5 962 N5 1,675 N5 1,195
Median days of follow-up
overalla
317 361 358 346 344 338 431
Median days of follow-up until
eventb
172 195 203 176 180 186 199
N switching to different biologic
DMARD
178 354 208 470 224 328 284
N discontinuing initiated
biologic DMARDc
286 498 196 571 258 377 304
Unadjusted probability of biologic DMARD therapy persistence, %d
1 year after initiation 51.5 46.9 53.3 46.3 45.4 53.1 47.7
2 years after initiation 38.8 31.9 35.9 36.4 29.0 42.4 36.4
ABA abatacept, ADA adalimumab, CZP certolizumab, DMARD disease-modifying antirheumatic drug, ETA etanercept,
GOL golimumab, INF inﬂiximab, TCZ tocilizumab
a Days from initiation until disenrollment or March 31, 2012
b Days from initiation to switch to a different biologic DMARD/discontinuation of the initiated biologic DMARD or
censoring at disenrollment or March 31, 2012
c Discontinuation is deﬁned as a 90-day gap in therapy
d Kaplan–Meier estimate
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initiation, unadjusted for demographic or
clinical characteristics. A total of 2,046
switches to a different biologic and 2,490
discontinuations were observed. At 1 year after
initiation, the probability of persisting on
therapy without switching or discontinuing
ranged from 45.5% in certolizumab-treated
patients to 53.3% in infliximab-treated
patients; at 2 years after initiation, these
probabilities ranged from 29.0% in
certolizumab-treated patients to 42.4% in
etanercept-treated patients.
Figure 2 displays the multivariable-adjusted
HRs for time to switch/discontinuation, treating
tocilizumab as reference category. Compared
with tocilizumab, the hazards of switching/
discontinuing biologic therapy were
significantly higher for adalimumab
(HR = 1.16, P = 0.014) and certolizumab
(HR = 1.15, P\0.012), but not significantly
different for abatacept (HR = 1.08, P = 0.229),
etanercept (HR = 0.97, P = 0.644), golimumab
(HR = 0.99, P = 0.829), and infliximab
(HR = 0.97, P = 0.721).
DISCUSSION
To our knowledge, this is the first study to
compare biologic therapy persistence between
biologic DMARDs among patients with RA who
have previously used at least one other biologic
agent. Compared with tocilizumab-treated
patients, the hazard of switching was
significantly higher for abatacept-treated
patients and anti-TNF-treated patients (except
in the case of etanercept) and the hazard of
switching/discontinuation was significantly
higher for adalimumab-treated patients and
certolizumab-treated patients. The relative
trends across the comparator (non-
tocilizumab) biologics were generally similar
for each of the two study endpoints, with
adalimumab- and certolizumab-treated
patients having the highest comparative
hazards of each endpoint and abatacept-,
etanercept-, golimumab-, and infliximab-
treated patients having relatively lower
comparative hazards. While we see
significantly longer time to switch for
Fig. 2 Multivariable-adjusted HRs for time to non-persis-
tence with biologic therapy (time to time to switch to
different biologic DMARD/discontinuation of the initi-
ated biologic DMARD), treating TCZ as reference cate-
gory. See Appendix in the Electronic Supplementary
Material for full multivariable analysis results. *P\0.05
vs. TCZ. ABA abatacept, ADA adalimumab, CI conﬁdence
interval, CZP certolizumab, DMARD disease-modifying
antirheumatic drug, ETA etanercept, GOL golimumab,
INF inﬂiximab, TCZ tocilizumab
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tocilizumab compared with abatacept,
golimumab and infliximab, there is no
difference between tocilizumab and these
agents when we look at the time to switch/
discontinuation endpoint. These findings show
that when we define discontinuation as a gap in
therapy, the persistence for tocilizumab is
similar to that of these three agents, implying
that tocilizumab patients might have a longer
gap in therapy before switching to a different
agent. Because our data source did not contain
detailed reasons as to why patients switch/
discontinue, we cannot conclude with
certainty as to why this happens.
Owing to the uniqueness of this
investigation, there are very few studies to
which these results can be compared. The
majority of studies examining biologic
therapy persistence rates among RA patients
have focused largely on the first-line setting
or have included only the anti-TNF agents
such as adalimumab, etanercept, and
infliximab [18–22]. One prior study by Ogale
et al. [11] described switching between
biologics among RA patients treated with
abatacept, adalimumab, etanercept,
infliximab, or rituximab in first- or
subsequent-line settings. Ogale et al. [11]
reported that in the subsequent-line setting,
adalimumab-treated patients had the highest
unadjusted rates of switching to a different
biologic (38.2%). The present study’s findings
were similar to those of Ogale et al. [11], with
unadjusted rates of switching at 1 year
equaling 29.1% for adalimumab-treated
patients. Furthermore, unadjusted rates of
switching at 1 year for abatacept were
similar between the two studies, with Ogale
et al. [11] reporting 23.4% and the present
study finding 26.5%. With the inclusion of
certolizumab, golimumab, and tocilizumab,
the present study contributes uniquely to the
body of research examining biologic therapy
persistence.
Among the covariates included in the
multivariable models, there were several
significant predictors of persistence. Predictors
with consistent direction and significance across
the twomodels included age (increase associated
with better persistence), the Deyo-Charlson
comorbidity index [increase (indicative of
greater comorbidity) associated with better
persistence], the number of non-biologic
DMARDs in the baseline period (increase
associated with better persistence), the number
of unique three-digit ICD-9-CM diagnoses in
baseline period (increase associated with slightly
worse persistence), and the number of unique
NDCs in the baseline period (increase associated
with slightly worse persistence). With few
exceptions, other covariates were generally
consistent in direction across the models and
statistically in significant. Although baseline use
of corticosteroids was not statistically
significantly associated with persistence, the
high baseline use rates of corticosteroids were
nevertheless notable, ranging from 69.5% in
golimumab-treated patients to 80.8% in
tocilizumab-treated patients. These rates were
similar to the rates previously reported by Ogale
et al. [11],whichamong subsequent-linepatients
ranged from69.9% in infliximab-treatedpatients
to 74.9% in abatacept-treated patients. Low-dose
corticosteroids therapy may be part of the
treatment strategy in combination with
DMARDs, though the appropriate duration of
therapy is debated due to the adverse event
profile of corticosteroids [1].
The 2010 EULAR and 2012 ACR
recommendations on RA management suggest
switching to a different DMARD when biologic-
treated patients experience treatment failure,
lack of efficacy, or toxicity [1, 2]. Because
administrative claims data do not posses
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clinical information regarding reasons for
switching and/or discontinuation, the present
study is unable to discern the underlying causes
of which differences in persistence may be
indicative. However, evidence from two
recently presented (in conferences)
observational studies including biologic-treated
patients from the United States (US) suggest that
among the various reasons for switching and/or
discontinuation, efficacy and tolerability/safety
account for at least half of all biologic
discontinuations [23, 24]. Strand et al. [23]
studied 6,209 biologic-treated RA patients
drawn from the US Consortium of
Rheumatology Researchers of North America
(CORRONA) database. They reported that
among those who discontinue or switch
therapy within the first year of treatment,
reasons for such changes included loss of
efficacy (35.8%), physician preference (27.8%),
safety concerns (20.1%), patient preference
(17.9%), or access to treatment (9.0%) [23].
Elkin et al. [24] studied medical charts of 176
RA patients from 8 centers in the US. These
patients had discontinued an anti-TNF as their
first biologic DMARD and had gone on to receive
a second biologic DMARD. The reported reasons
for this change were failure tomaintain response
(46.6%), lack of initial efficacy (22.7%), safety/
tolerance (17.0%), cost, insurance, or formulary-
relatedmatters (7.4%), other orunknown (7.4%),
and patient or physician preference (0.6%) [24].
Evidence from populations outside of the US has
also been consistent with the findings from the
two aforementioned studies [3–5]. Thus, it is
plausible that the switching and discontinuation
patterns observed in the present study may be
indicative of undesirable clinical circumstances
such as treatment failure due to lack of efficacy or
adverse events.
This study was subject to limitations.
Administrative claims data are not collected
for research purposes and the procedure and
diagnosis coding on administrative claims data
is recorded by healthcare practitioners to
support reimbursement. Thus, miscoded or
non-coded administrative claims can result in
measurement error when measuring variables
that rely on such coding. Because
administrative claims data do not provide
detailed clinical information, we do not know
why patients may have switched to a different
biologic. We required that all study patients
have previously used at least one other biologic.
It is possible that if a patient has failed multiple
biologics, a patient’s physician or the patient
him- or herself may be less likely to switch to an
alternative therapy. If tocilizumab is reserved
for later lines of therapy, this could potentially
explain the lower hazards of switching among
tocilizumab-treated patients. To investigate
this, we quantified the average number of
observed biologics used prior to initiation of
treatment for each biologic group, with the
limitation that these data are left-censored. We
found that the average number of observed
prior biologics differed very little, by only one-
tenth, across the biologic groups:
tocilizumab = 1.3 prior biologics, abatacept =
1.2, infliximab = 1.3, adalimumab = 1.2,
certolizumab = 1.3, etanercept = 1.2, and
golimumab = 1.2. Similarly, the proportion of
patients with at least three prior biologics
differed little across the biologic groups:
tocilizumab = 4%, abatacept = 3%,
infliximab = 4%, adalimumab = 2%,
certolizumab = 4%, etanercept = 2%, and
golimumab = 3%.
The study databases did not include
information on patients’ education or socio-
economic status, which may affect their access
to, and ability to pay for, biologic treatments.
This limitation is tempered by the fact that all
patients included in the study were required to
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have initiated biologic therapy and had
previously used at least one other biologic.
Therefore it is known that they have access to
more than one biologic treatment.
Furthermore, the fact that they have been
treated with more than one biologic is
suggestive that economic limitations may be
less important for the studied population than
individuals, who had alternative coverage such
as Medicaid insurance. Finally, these results are
not generalizable to the entire US RA
population, including those who are
uninsured or insured through Medicaid.
CONCLUSION
Among patients with RA who previously used at
least one other biologic, tocilizumab-treated
patients had similar or significantly better
biologic persistence compared with other
biologics. Such persistence differences may be
reflective of treatment failure, inadequate
response, side effects, or other reasons. This
study’s findings may provide insights into the
comparative effectiveness of biologic agents
when used in the real-world setting,
specifically among patients with RA who are
not naı¨ve to biologic treatment.
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